These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 26818483)

  • 1. Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.
    Gill KL; Machavaram KK; Rose RH; Chetty M
    Clin Pharmacokinet; 2016 Jul; 55(7):789-805. PubMed ID: 26818483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A guide to rational dosing of monoclonal antibodies.
    Bai S; Jorga K; Xin Y; Jin D; Zheng Y; Damico-Beyer LA; Gupta M; Tang M; Allison DE; Lu D; Zhang Y; Joshi A; Dresser MJ
    Clin Pharmacokinet; 2012 Feb; 51(2):119-35. PubMed ID: 22257150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
    Gurbaxani B; Dostalek M; Gardner I
    Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding Inter-Individual Variability in Monoclonal Antibody Disposition.
    Thomas VA; Balthasar JP
    Antibodies (Basel); 2019 Dec; 8(4):. PubMed ID: 31817205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetic variability of therapeutic antibodies].
    Ternant D; Chhun S
    Med Sci (Paris); 2019 Dec; 35(12):1130-1136. PubMed ID: 31903927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of FcRn binding assays to guide mAb development.
    Datta-Mannan A; Wroblewski VJ
    Drug Metab Dispos; 2014 Nov; 42(11):1867-72. PubMed ID: 25024401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human FcRn Transgenic Mice for Pharmacokinetic Evaluation of Therapeutic Antibodies.
    Roopenian DC; Christianson GJ; Proetzel G; Sproule TJ
    Methods Mol Biol; 2016; 1438():103-14. PubMed ID: 27150086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins.
    Ternant D; Paintaud G
    Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S37-47. PubMed ID: 16187939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
    Glassman PM; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.
    Dostalek M; Gardner I; Gurbaxani BM; Rose RH; Chetty M
    Clin Pharmacokinet; 2013 Feb; 52(2):83-124. PubMed ID: 23299465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.
    Ternant D; Bejan-Angoulvant T; Passot C; Mulleman D; Paintaud G
    Clin Pharmacokinet; 2015 Nov; 54(11):1107-23. PubMed ID: 26123705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development.
    Mould DR; Sweeney KR
    Curr Opin Drug Discov Devel; 2007 Jan; 10(1):84-96. PubMed ID: 17265746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.
    Datta-Mannan A; Lu J; Witcher DR; Leung D; Tang Y; Wroblewski VJ
    MAbs; 2015; 7(6):1084-93. PubMed ID: 26337808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study.
    Zheng Y; Scheerens H; Davis JC; Deng R; Fischer SK; Woods C; Fielder PJ; Stefanich EG
    Clin Pharmacol Ther; 2011 Feb; 89(2):283-90. PubMed ID: 21191378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications.
    Bensalem A; Ternant D
    Clin Pharmacokinet; 2020 Jul; 59(7):857-874. PubMed ID: 32170579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development.
    Mould DR; Green B
    BioDrugs; 2010 Feb; 24(1):23-39. PubMed ID: 20055530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies.
    Malik P; Edginton A
    Expert Opin Drug Metab Toxicol; 2018 Jun; 14(6):585-599. PubMed ID: 29806953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children.
    Edlund H; Melin J; Parra-Guillen ZP; Kloft C
    Clin Pharmacokinet; 2015 Jan; 54(1):35-80. PubMed ID: 25516414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
    Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
    Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys.
    Datta-Mannan A; Chow CK; Dickinson C; Driver D; Lu J; Witcher DR; Wroblewski VJ
    Drug Metab Dispos; 2012 Aug; 40(8):1545-55. PubMed ID: 22584253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.